'''Ubenimex''' ([[International Nonproprietary Name|INN]]), also known more commonly as '''bestatin''', is a competitive, reversible [[Protease inhibitor (pharmacology)|protease inhibitor]]. It is an [[enzyme inhibitor|inhibitor]] of [[arginyl aminopeptidase]] (aminopeptidase B),<ref>{{cite journal | year = 1976 | issue = 29 | pages = 97–99 | title = Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes.| author = Umezawa, H.| author2 = Aoyagi, T.| author3 = Suda, H.| author4 = Hamada, M.| author5 = Takeuchi, T.}}</ref> [[leukotriene A4 hydrolase|leukotriene A<sub>4</sub> hydrolase]] (a [[zinc metalloprotease]] that displays both [[epoxide hydrolase]] and [[aminopeptidase]] activities),<ref>{{cite journal | year = 1994 | issue = 48 | pages = 131–137 | title = Modulation of pulmonary leukotriene formation and perfusion pressure by Bestatin, an inhibitor of leukotriene A4 hydrolase.| author = Muskardin, D.T.| author2 = Voelkel, N.F.| author3 = Fitzpatrick, F.A.}}</ref> [[alanyl aminopeptidase]] (aminopeptidase M/N),<ref>{{cite journal | year = 1999 | issue = 5 | pages = 729–734 | title = Induction of apoptosis by Bestatin (ubenimex) in human leukemic cell lines |author1=K Sekine |author2=H Fujii |author3=F Abe | volume = 13}}</ref> [[leucyl/cystinyl aminopeptidase]] (oxytocinase/vasopressinase),<ref name="pmid10985965">{{cite journal | vauthors = Nakanishi Y, Nomura S, Okada M, Ito T, Katsumata Y, Kikkawa F, Hattori A, Tsujimoto M, Mizutani S | title = Immunoaffinity purification and characterization of native placental leucine aminopeptidase/oxytocinase from human placenta | journal = Placenta | volume = 21 | issue = 7 | pages = 628–34 | year = 2000 | pmid = 10985965 | doi = 10.1053/plac.2000.0564 | url = }}</ref><ref name="pmid8801531">{{cite journal | vauthors = Naruki M, Mizutani S, Goto K, Tsujimoto M, Nakazato H, Itakura A, Mizuno K, Kurauchi O, Kikkawa F, Tomoda Y | title = Oxytocin is hydrolyzed by an enzyme in human placenta that is identical to the oxytocinase of pregnancy serum | journal = Peptides | volume = 17 | issue = 2 | pages = 257–61 | year = 1996 | pmid = 8801531 | doi = 10.1016/0196-9781(95)02124-8| url = }}</ref> and [[membrane dipeptidase]] (leukotriene D<sub>4</sub> hydrolase). It is being studied for use in the treatment of [[acute myelocytic leukemia]]<ref>{{Cite journal | pmid = 12938265 | year = 2003 | last1 = Hirayama | first1 = Y | last2 = Sakamaki | first2 = S | last3 = Takayanagi | first3 = N | last4 = Tsuji | first4 = Y | last5 = Sagawa | first5 = T | last6 = Chiba | first6 = H | last7 = Matsunaga | first7 = T | last8 = Niitsu | first8 = Y | title = Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients--effects, complications and long-term survival | volume = 30 | issue = 8 | pages = 1113–8 | journal = Gan to kagaku ryoho. Cancer & chemotherapy}}</ref> and [[lymphedema]]<ref>{{Cite journal | pmid = 28490670 | year = 2017 | last1 = Tian | first1 = W | last2 = Rockson | first2 = S | last3 = Jiang | first3 = X | last4 = Kim | first4 = J | last5 = Begaye | first5 = A | last6 = Shuffle | first6 = EM | last7 = Tu | first7 = AB | last8 = Cribb | first8 = M | last9 = Nepiyushchikh | first9 = Z | last10 = Feroze | first10 = AH | last11 = Zamanian | first11 = RT | last12 = Dhillon | first12 = RT | last13 = Voelkel | first13 = NF | last14 = Peters-Golden | first14 = M | last15 = Kitajewski | first15 = J | last16 = Dixon | first16 = JB | last17 = Nicolls | first17 = MR | title = Leukotriene B4 antagonism ameliorates experimental lymphedema | volume = 9 | issue = 389 | pages = eaal3920 | journal = Science Translational Medicine}}</ref>.
